The Patients Before Monopolies Act, or PBM Act, would prohibit a person or company from both owning or controlling a pharmacy and owning or controlling an insurance company or pharmacy benefit manager (PBM). The bill is aimed at vertically integrated health care conglomerates that combine PBM, insurer, and pharmacy operations, which the bill says can steer patients to affiliated pharmacies, reduce competition, and raise prescription drug costs. It also cites concerns that these structures can pressure independent pharmacies and contribute to pharmacy closures, while allowing profits to be shifted in ways that may evade medical loss ratio limits.
If enacted, the bill would require covered entities to divest pharmacy holdings within one year of enactment. It gives the Federal Trade Commission and the Department of Justice Antitrust Division authority to enforce the ban, issue divestiture guidance, impose escrow penalties for noncompliance, appoint divestiture trustees, and block future transactions that would recreate the prohibited conflicts. The bill also creates civil enforcement tools for federal officials, state attorneys general, and private plaintiffs, including treble damages, disgorgement, injunctive relief, and a fund for harmed communities. It further requires FTC rulemaking and quarterly compliance reports to Congress.
The bill would create a new federal structural separation rule affecting pharmacies, PBMs, and insurers, and would override existing business models in which those functions are commonly held under one corporate umbrella. It would expand federal antitrust-style oversight by requiring divestitures, mandating transaction reporting under the Clayton Act, and authorizing FTC and DOJ review of both divestitures and subsequent acquisitions. The measure would also affect state-regulated pharmacy operations and state attorneys general by expressly allowing state enforcement actions and private lawsuits, while defining pharmacy and PBM broadly to cover retail, mail-order, specialty, hospital, long-term care, and other pharmacy types.
The bill appears to have a reform-oriented, anti-monopoly framing and is sponsored by senators from both parties, suggesting some bipartisan interest in addressing PBM and pharmacy consolidation. The findings section reflects a strong policy judgment that current vertical integration harms competition, independent pharmacies, patients, and taxpayers. No committee transcript or vote record is provided, so there is no recorded floor or committee sentiment beyond the bill’s text and sponsorship.
The main point of contention is whether vertically integrated PBM-insurer-pharmacy ownership should be treated as an anticompetitive conflict of interest that requires forced divestiture, or as a legitimate business structure that can improve efficiency and coordination. The bill’s broad divestiture mandate, escrow penalties, and private right of action are likely to draw opposition from PBMs, insurers, and integrated health conglomerates, while independent pharmacies, patient advocates, and antitrust supporters are likely to favor it. Another likely dispute is federal preemption and the scope of FTC/DOJ authority over transactions and state-level enforcement.